New Harbor Capital Acquires Majority Interest in LGM Pharma

New Harbor Capital

Chicago-based private equity firm New Harbor Capital completed a majority equity investment in LGM Pharma, an innovation-driven company involved in distribution of cGMP active pharmaceutical ingredients (“API”) and other value-added services supporting leading pharmaceutical companies.

LGM specializes in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory support for a wide range of products. The company serves many active customers across biotech, generic pharma, contract manufacturing, specialty pharma, CDMOs, academic institutes, compounding and pharmaceutical manufacturing industries, supporting all stages of drug development and commercialization by supplying a wide range of APIs and by providing other value-added services.

New Harbor Capital Acquires Majority Interest in LGM Pharma
Gideon Schurder, Commercial Director & Mendy Schurder, Director/COO

“We welcome LGM to our growing healthcare portfolio,” said Jocelyn Stanley, Principal at New Harbor Capital. “We are excited to partner with LGM’s co-founders Mendy and Gideon Schurder to support efforts to strategically grow the business.”

“New Harbor’s investment marks an important milestone in LGM Pharma’s history,” said Mendy Schurder, COO. “With the healthcare network, strategic vision and capital that New Harbor brings to LGM, we look forward to expanding our service offerings while continuing to invest in the substantial growth of our company.”

“New Harbor’s strong track record of successfully executing growth strategies, as well as their experience with the healthcare industry and pharmaceutical services, will elevate our business to the next level while upholding the high quality, innovation and reliable service our customers expect,” said Gideon Schurder, Commercial Director. “New Harbor shares our vision for expanding LGM’s services and capabilities with a focus on putting quality first and we are thrilled to have them as partners.”

About LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. LGM specializes in providing integrated sourcing options, complete technical capabilities and regulatory documentation support for a wide range of APIs.

About New Harbor Capital

New Harbor Capital is a Chicago-based private equity firm with over $400 million of capital under management, focused on investing in lower middle market, growth-oriented healthcare, education and business services companies. Our Partners have been private equity investors for over 20 years, partnering with strong management teams to systematically enable accelerated growth in value creation. Since 2000, the New Harbor team has completed over 200 investments. As an experienced strategic partner, New Harbor supports management with ideas, connections and resources to capitalize on growth potential.

For more information, visit

Related Posts

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities
—50% expansion and over $2 million investment in standalone analytical testing services (ATS); offers...
Read More >
─CDMO Clinical and Commercial Manufacturing Services, Including Analytical Testing and Drug Product R&D...
Read More >
LGM pharma’s unique mix of API sourcing and CDMO services is fueling robust growth
─Customer Projects Bridging LGM Pharma’s API Sourcing and CDMO Services Range from Promising Pharmaceutical...
Read More >

Latest Posts